Takeda and Evotec SE entered into a multiyear partnership to develop new drug therapies.
What you should know:
1. The partnership aims to develop at least five drug discovery programs. Evotec aims to deliver clinical candidates to Takeda, which can then take them through clinical development.
2. The program will target Takeda's four key development areas: oncology, gastroenterology, neuroscience and rare disease.
3. Takeda paid Evotec a one-time, upfront fee. Evotec is eligible for several milestone-related payments totaling more than $170 million per program, and Evotec will be paid royalties on future sales.